A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in Chronic Kidney Disease DOI

Armin Ahmadi,

Ana P. Valencia, Gwénaëlle Begue

et al.

Clinical Journal of the American Society of Nephrology, Journal Year: 2025, Volume and Issue: 20(3), P. 346 - 357

Published: Jan. 23, 2025

Key Points Nicotinamide riboside and coenzyme Q10 supplementation showed distinct beneficial effects on whole-blood transcriptome, inflammatory cytokines, oxidative stress. treatment altered the expression of genes associated with metabolism immune response coinciding a decrease in markers Coenzyme lipid reductions stress cytokines. Background Mitochondria-driven oxidative/redox inflammation play major role CKD pathophysiology. Compounds targeting mitochondrial may improve function, inflammation, redox stress; however, there is limited evidence their efficacy CKD. Methods We conducted pilot, randomized, double-blind, placebo-controlled crossover trial comparing 1200 mg/d (CoQ10) or 1000 nicotinamide (NR) placebo 25 patients moderate-to-severe (eGFR <60 ml/min per 1.73 m 2 ). assessed changes blood transcriptome using 3′-Tag-Seq gene profiling prespecified secondary outcomes biomarkers. For subsample participants ( n =14), we lymphocyte monocyte bioenergetics an extracellular flux analyzer. Results The (mean±SD) age, eGFR, body mass index were 61±11 years, 37±9 , 28±5 kg/m respectively. Of participants, 16% had diabetes 40% female. Compared placebo, NR-mediated transcriptomic enriched ontology terms carbohydrate/lipid signaling, whereas CoQ10 immune/stress terms. NR increased plasma IL-2 (estimated difference, 0.32; 95% confidence interval [CI], 0.14 to 0.49 pg/ml), decreased both IL-13 −0.12; CI, −0.24 −0.01 pg/ml) C-reactive protein −0.11; −0.22 0.00 mg/dl) compared placebo. Both reduced five-series F2-isoprostanes −0.16 −0.11 pg/ml, respectively; P < 0.05 for both). NR, but not CoQ10, Bioenergetic Health Index 0.29; 0.06 0.53) spare respiratory capacity 3.52; 0.04 7 pmol/min 10,000 cells) monocytes. Conclusions Six weeks improved stress, cell Clinical Trial registry name registration number: NCT03579693.

Language: Английский

Mitochondrion: The Subordinated Partner Who Agreed to Come Short But Insists in Healthy Life DOI
Olga Golubnitschaja

Advances in predictive, preventive and personalised medicine, Journal Year: 2024, Volume and Issue: unknown, P. 17 - 29

Published: Jan. 1, 2024

Language: Английский

Citations

5
Application of ChatGPT-4 to oculomics: a cost-effective osteoporosis risk assessment to enhance management as a proof-of-principles model in 3PM DOI
Joon Yul Choi,

Eoksoo Han,

Tae Keun Yoo

et al.

The EPMA Journal, Journal Year: 2024, Volume and Issue: 15(4), P. 659 - 676

Published: Aug. 28, 2024

Language: Английский

Citations

5
Mitochondria-based holistic 3PM approach as the ‘game-changer’ for individualised rehabilitation—the proof-of-principle model by treated breast cancer survivors DOI Creative Commons
Martin Pešta,

Barbara Mrazova,

Marko Kapalla

et al.

The EPMA Journal, Journal Year: 2024, Volume and Issue: 15(4), P. 559 - 571

Published: Nov. 20, 2024

Breast cancer belongs to the most commonly diagnosed malignancies worldwide, with its increasing incidence paralleled by advances in early diagnostics and effective treatments resulting significantly improved survival rates. However, breast survivors often experience reduced quality of life linked long-term health burden as a consequence aggressive oncological applied. Their frequently recorded complains include chronic fatigue, physical activity, disordered sleep, chronification pain, severe mental impairments-all per evidence are associated compromised mitochondrial impaired homeostasis. Self-report survivor is included this article illustrate currently uncovered patient needs. This highlights mechanisms behind suboptimal damage, introduces novel, mitochondria-based holistic approach addressing rehabilitation concepts for following advanced principles predictive, preventive personalised medicine (3PM). By operating via function, proposed triggers systemic effects at molecular, sub/cellular organismal levels positively affecting energy metabolism, repair well creating, therefore, highly algorithms tailored an individualised profile. The methodology integrates assessments utilising homeostasis biomarkers tear fluid non-invasive diagnostic tool, nutraceuticals lifestyle adjustments. introduced aligns 3PM, offering proactive framework managing persistent post-treatment symptoms cohort survivors. Furthermore, presented also applicable pre-habilitation programmes considering needs other cohorts affected diseases such CVD orthopaedic disorders planned major surgical incisions, who require individually adapted pre- programmes. Implementing innovative strategies may lead full recovery, sustainable conditions and, facilitating patients' comeback normal daily activities, family professional life. Contextually, considered 'proof-of-principle' model 3PM-related paradigm shift from reactive cost-effective management both primary secondary care benefiting large spectrum cohorts, individuals society large.

Language: Английский

Citations

5
Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach DOI
Jingru Yang, Serge Yannick Ouédraogo, Jingjing Wang

et al.

The EPMA Journal, Journal Year: 2024, Volume and Issue: 15(1), P. 67 - 97

Published: March 4, 2024

Language: Английский

Citations

4
A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in Chronic Kidney Disease DOI

Armin Ahmadi,

Ana P. Valencia, Gwénaëlle Begue

et al.

Clinical Journal of the American Society of Nephrology, Journal Year: 2025, Volume and Issue: 20(3), P. 346 - 357

Published: Jan. 23, 2025

Key Points Nicotinamide riboside and coenzyme Q10 supplementation showed distinct beneficial effects on whole-blood transcriptome, inflammatory cytokines, oxidative stress. treatment altered the expression of genes associated with metabolism immune response coinciding a decrease in markers Coenzyme lipid reductions stress cytokines. Background Mitochondria-driven oxidative/redox inflammation play major role CKD pathophysiology. Compounds targeting mitochondrial may improve function, inflammation, redox stress; however, there is limited evidence their efficacy CKD. Methods We conducted pilot, randomized, double-blind, placebo-controlled crossover trial comparing 1200 mg/d (CoQ10) or 1000 nicotinamide (NR) placebo 25 patients moderate-to-severe (eGFR <60 ml/min per 1.73 m 2 ). assessed changes blood transcriptome using 3′-Tag-Seq gene profiling prespecified secondary outcomes biomarkers. For subsample participants ( n =14), we lymphocyte monocyte bioenergetics an extracellular flux analyzer. Results The (mean±SD) age, eGFR, body mass index were 61±11 years, 37±9 , 28±5 kg/m respectively. Of participants, 16% had diabetes 40% female. Compared placebo, NR-mediated transcriptomic enriched ontology terms carbohydrate/lipid signaling, whereas CoQ10 immune/stress terms. NR increased plasma IL-2 (estimated difference, 0.32; 95% confidence interval [CI], 0.14 to 0.49 pg/ml), decreased both IL-13 −0.12; CI, −0.24 −0.01 pg/ml) C-reactive protein −0.11; −0.22 0.00 mg/dl) compared placebo. Both reduced five-series F2-isoprostanes −0.16 −0.11 pg/ml, respectively; P < 0.05 for both). NR, but not CoQ10, Bioenergetic Health Index 0.29; 0.06 0.53) spare respiratory capacity 3.52; 0.04 7 pmol/min 10,000 cells) monocytes. Conclusions Six weeks improved stress, cell Clinical Trial registry name registration number: NCT03579693.

Language: Английский

Citations

0